浩鼎 (4174.TWO)

60.10 -0.70 (-1.15%) 收市：01:30PM CST

浩鼎

No. 508, Sec. 7
6th Floor Zhongxiao E. Rd. Nangang District
Taipei 115
Taiwan
886 2 2786 6589
https://www.obipharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Ming-Tien Lai	Chief Scientific Officer	7.73M	無	無
Mr. Cheng-En Tsai	VP of Medical Department & Director	7.38M	無	無
Dr. Heidi Wang Ph.D.	Chief Executive Officer	無	無	無
Mr. Colin Kao	CFO, Accounting Supervisor & Corporate Governance Supervisor	無	無	無
Mr. Po-Jen Chang	Director of Human Resources & Administration	無	無	無
Ms. Sharon Lee	Director of Public Affairs	無	無	無
Mr. Kevin P. Poulos	Chief Business Officer	無	無	1959
Dr. Wayne Saville M.D.	Chief Medical Officer	無	無	無
Dr. Dong Xu Ph.D.	Senior Vice President of Biostatistics & Data Management	無	無	無
Mr. Chun-Hung Chou	Vice President of Chemical Pharmacy and R&D Office	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.

公司管治

截至 無 止，浩鼎 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。